PBS listings to save melanoma and multiple sclerosis patients up to $128,900 a year
Australians suffering from melanoma and multiple sclerosis will soon have new treatment options, with new and amended PBS listings on the Pharmaceutical Benefits Scheme (PBS) coming into effect on 1 November. The Morrison Government will expand the current PBS listings of Tafinlar® (dabrafenib) and Mekinist® (trametinib) to include subsidy for post-surgery treatment for patients…